- Home
- TNXP vs NYXH Comparison
TNXP vs NYXH Comparison
Compare TNXP & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- NYXH
- Stock Information
- Founded
- TNXP 2007
- NYXH 2009
- Country
- TNXP United States
- NYXH Belgium
- Employees
- TNXP N/A
- NYXH N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- TNXP Health Care
- NYXH Health Care
- Exchange
- TNXP Nasdaq
- NYXH Nasdaq
- Market Cap
- TNXP 272.0M
- NYXH 290.9M
- IPO Year
- TNXP N/A
- NYXH 2021
- Fundamental
- Price
- TNXP $49.73
- NYXH $7.58
- Analyst Decision
- TNXP Strong Buy
- NYXH Strong Buy
- Analyst Count
- TNXP 2
- NYXH 4
- Target Price
- TNXP $585.00
- NYXH $14.50
- AVG Volume (30 Days)
- TNXP 1.2M
- NYXH 32.2K
- Earning Date
- TNXP 08-15-2025
- NYXH 08-05-2025
- Dividend Yield
- TNXP N/A
- NYXH N/A
- EPS Growth
- TNXP N/A
- NYXH N/A
- EPS
- TNXP N/A
- NYXH N/A
- Revenue
- TNXP $10,041,000.00
- NYXH $4,716,818.00
- Revenue This Year
- TNXP $22.87
- NYXH $323.07
- Revenue Next Year
- TNXP $711.66
- NYXH $204.30
- P/E Ratio
- TNXP N/A
- NYXH N/A
- Revenue Growth
- TNXP N/A
- NYXH N/A
- 52 Week Low
- TNXP $6.76
- NYXH $5.55
- 52 Week High
- TNXP $130.00
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- TNXP 70.46
- NYXH 44.38
- Support Level
- TNXP $41.64
- NYXH $7.65
- Resistance Level
- TNXP $46.00
- NYXH $8.37
- Average True Range (ATR)
- TNXP 3.70
- NYXH 0.26
- MACD
- TNXP 0.38
- NYXH -0.04
- Stochastic Oscillator
- TNXP 95.84
- NYXH 18.56
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.